In:
European Journal of Haematology, Wiley, Vol. 105, No. 2 ( 2020-08), p. 196-202
Kurzfassung:
Little is reported on the real‐life impact of daratumumab in relapsed and/or refractory multiple myeloma patients (RRMM). We analyzed a cohort of 156 patients who received daratumumab as a single agent concerning ECOG status, eGFR, cytogenetics, lines of prior treatment, and their impact on survival. Results Eighty‐two (53%) patients were triple refractory, 54 (35%) patients were single or double refractory, and 20 (12%) patients were non‐refractory. Following daratumumab treatment, the progression‐free survival (PFS) in these groups was 7.2%, 11.4%, and 53% ( P 〈 .001), and overall survival (OS) was 34%, 73%, and 58% ( P 〈 .001) at 36 months, respectively. Poor ECOG, three lines of prior treatment, and triple refractoriness were all associated with inferior PFS and OS in a multivariate analysis including ECOG, high‐risk chromosomal aberrations, refractoriness, number of treatment lines, and eGFR. Conclusion Daratumumab remains an attractive treatment option, especially in patients with poor performance and increased frailty. Furthermore, our observations suggest that patients with ECOG 2 and 3 status require additional supportive and/or palliative therapies to compensate for a potentially effective but encompassing late‐line therapy. In conclusion, further prospective studies are needed to elucidate the impact of ECOG 2 and 3 status in patients with RRMM.
Materialart:
Online-Ressource
ISSN:
0902-4441
,
1600-0609
Sprache:
Englisch
Verlag:
Wiley
Publikationsdatum:
2020
ZDB Id:
2027114-1
